About sotatercept
Activin signaling inhibitor
Used for
- Treats adults with pulmonary arterial hypertension to improve exercise ability and reduce risk of worsening.
Usual adult dose
Usually 0.3 mg/kg under the skin every 3 weeks initially, increasing to 0.7 mg/kg every 3 weeks if blood tests allow.
Common side effects
- Nosebleeds
- Headache
- Rash or visible small blood vessels
- Low platelet counts or increased hemoglobin
Important warnings
- Requires blood tests before each of the first five doses and periodically afterward.
- May cause serious bleeding, especially with low platelets or blood-thinning medicines.
- Can cause severe increases in hemoglobin; treatment may need interruption or dose changes.
- May harm an unborn baby; pregnancy testing and effective contraception are recommended.
Pregnancy
May cause fetal harm. Avoid during pregnancy; effective contraception is recommended during treatment and for at least 4 months after the last dose.
Breastfeeding
It is unknown whether sotatercept passes into human milk. Breastfeeding is not recommended during treatment and for 4 months after the last dose.
Interactions
- Anticoagulants and antiplatelet medicines may increase bleeding risk.
- Medicines that lower platelets may increase bleeding risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.